| 1078 Hypocholesterolaemia in chronic hepatitis c genotype 3 infection is due to both reduced cholesterol production and increased ldl clearance D Sheridan, K Bartlett, D Felmlee, SH Bridge, GL Toms, G Dubuc, S Nabil, ... Journal of Hepatology, S417, 2010 | 1 | 2010 |
| 326 OBESITY-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE REGENERATE STUDY ZM Younossi, M Stepanova, F Nader, R Loomba, QM Anstee, V Ratziu, ... Gastroenterology 158 (6), S-1268, 2020 | 1 | 2020 |
| 686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED … AE Kremer, MJ Mayo, CL Bowlus, G Neff, MG Swain, M Galambos, A Goel, ... Gastroenterology 158 (6), S-1284-S-1285, 2020 | 1 | 2020 |
| 8 Thinking ahead clinic A Moffat, D Sheridan BMJ Supportive & Palliative Care 9 (Suppl 1), A3-A3, 2019 | | 2019 |
| 869 CHARACTERIZATION OF HEPATITIS C VIRUS PARTICLES IN HUMAN PLASMA: ASSOCIATION WITH IMMUNOGLOBULINS G1, G3 & M AND APOLIPOPROTEINS AI, A-II, B, CI AND E S Nielsen, D Sheridan, S Bridge, D Felmlee, D Neely, G Toms, ... Journal of Hepatology, S316-S317, 2009 | | 2009 |
| 903 OMEGA-3 FATTY ACIDS AND/OR FLUVASTATIN IN HEPATITIS C PRIOR NON-RESPONDERS TO COMBINATION ANTI-VIRAL THERAPY–A PILOT RANDOMISED CLINICAL TRIAL DA Sheridan, SH Bridge, MME Crossey, DJ Felmlee, F Fenwick, ... Journal of Hepatology, S372, 2013 | | 2013 |
| 938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH Z Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... Official journal of the American College of Gastroenterology| ACG 114, S546, 2019 | 2 | 2019 |
| A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis DA Sheridan, CM Stanca, CP Berg, A Goel, ML Shiffman, JM Vierling, ... | | |
| A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis CL Bowlus, MR Galambos, RJ Aspinall, GM Hirschfield, DEJ Jones, ... Journal of hepatology 77 (2), 353-364, 2022 | 48 | 2022 |
| A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms RE Sharkawy, A Bayoumi, M Metwally, A Mangia, T Berg, ... Scientific reports 9 (1), 1439, 2019 | 13 | 2019 |
| Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease PJ Eddowes, M Sasso, M Allison, E Tsochatzis, QM Anstee, D Sheridan, ... Gastroenterology 156 (6), 1717-1730, 2019 | 1050 | 2019 |
| Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease E Tsochatzis, PJ Eddowes, M Sasso, M Allison, E Tsochatzis, QM Anstee, ... Gastroenterology 156 (6), 0 | | |
| Acute myeloid leukaemia: An unusual cause of biliary strictures A Beck, H Hunter, S Jackson, D Sheridan BMJ Case Reports CP 12 (3), e227821, 2019 | 1 | 2019 |
| Algorithm to identify patients with an activity grade> 2 in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD)-development in a large prospective … P Eddowes, M Allison, E Tsochatzis, Q Anstee, D Sheridan, IN Guha, ... Journal of Hepatology 68, S552-S553, 2018 | 1 | 2018 |
| An audit of the management of osteoporosis associated with chronic liver disease DA Sheridan, CE MacDonald GUT 56, A132-A133, 2007 | | 2007 |
| Apolipoprotein B associated cholesterol level is a predictor of response to therapy in chronic hepatitis C DA Sheridan, DA Price, ML Schmid, PT Donoldsonl, GL Toms, D Neely, ... Hepatology: 59th Annual Meeting of the American Association for the Study of …, 2008 | | 2008 |
| APOLIPOPROTEIN B ASSOCIATED HEPATITIS C VIRUS (HCV): A MINORITY OF TOTAL VIRAL LOAD IN PATIENTS WITH CHRONIC HCV: 1634 S Bridge, DA Sheridan, D Felmlee, SU Nielsen, D Neely, GL Toms, ... Hepatology 50, 1061A, 2009 | | 2009 |
| Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha … DA Sheridan, DA Price, ML Schmid, GL Toms, P Donaldson, D Neely, ... Alimentary pharmacology & therapeutics 29 (12), 1282-1290, 2009 | 55 | 2009 |
| APOLIPOPROTEIN E AND LOW-DENSITY, APOLIPOPROTEIN B ASSOCIATED LIPOVIRAL PARTICLES IN CHRONIC HEPATITIS C INFECTION: EVIDENCE FOR GENOTYPE-SPECIFIC MODULATION OF LIPID PATHWAYS … SH Bridge, DA Sheridan, D Felmlee, H Thomas, M Crossey, ... Hepatology 54 (4), 1316A, 2011 | | 2011 |
| Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity DA Sheridan, SH Bridge, DJ Felmlee, MME Crossey, HC Thomas, ... Journal of hepatology 57 (1), 32-38, 2012 | 47 | 2012 |
Margaret BassendineVerified email at ncl.ac.uk